November 19-20, 2020
2020 Drugging Autophagy Summit
Genoscience Pharma has presented at The Drugging Autophagy Summit its Phase 1b results, where all…
Read More
Nov. 18, 2020
GNS561’s successful phase 1b trial completed
Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
July 22, 2020
GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
18 June, 2020
Our COVID-19 research Project supported by the French Government
Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
June 22-24, 2020
AACR 2020 Virtual Annual Meeting
GENOSCIENCE PHARMA Announces Remarkable Data on GNS561 in Combination with anti-PD1 to be Presented at…
Read More
April 6, 2020
COVID-19, GNS561’s Assault begins in France !
Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…
Read More
January 13, 2020
ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology
Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
January 13-15, 2020
Biotech Showcase™ 2020
Biotech Showcase™ 2020 - San Francisco, California Investor conference We will be present during…
Read More
December 16, 2019
GNS561 to treat pancreas or colorectal cancer with liver metastasis
GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
December 2, 2019
The GoforIsrael Investment Conference 2019
The GoforIsrael - Investment Conference 2019 - Tel Aviv, Israel We are honored to…
Read More
